Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

NKTR

+ Watchlist+ Portfolio

Nektar Therapeutics

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$35.91
52-Week Range
$33.40 – $109.00
Market Cap
$1.18B
P/E (TTM)
—
EPS (TTM)
-22.47
Dividend Yield
0.00%
Advanced Metrics
Price/Book
1.39
PEG Ratio
0.31
Return on Equity
-37.92%
Return on Assets
-14.79%
Gross Margin
100.00%
Operating Margin
-303.57%
Profit Margin
0.00%
Current Ratio
9.00
Debt/Equity
0.15
Total Debt
$128.67M
Free Cash Flow
$-152.10M
Revenue Growth
-20.40%
Earnings Growth
—
Enterprise Value
$691.98M

Market Snapshot

About

Nektar Therapeutics is a biopharmaceutical company developing innovative therapies in immuno-oncology and immunology using its proprietary drug platform technologies. The company focuses on polymer conjugate technology to modify and optimize drug candidates. Nektar has multiple clinical-stage programs aimed at treating cancer and autoimmune diseases.